Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the Absence of Acute Coronary Syndrome
Top Cited Papers
Open Access
- 1 January 2012
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (1), 209-218
- https://doi.org/10.1373/clinchem.2011.171827
Abstract
BACKGROUND: We evaluated kinetic changes of high-sensitivity cardiac troponin T (hs-cTnT) in patients with acute coronary syndrome (ACS) and patients with hs-cTnT increases not due to ACS to rule in or rule out non–ST-segment elevation myocardial infarction (STEMI). METHODS: hs-cTnT was measured serially in consecutive patients presenting to the emergency department. Patients with ACS who had at least 2 hs-cTnT measurements within 6 h and non-ACS patients with hs-cTnT concentrations above the 99th percentile value (14 ng/L) were enrolled to compare absolute and relative kinetic changes of hs-cTnT. RESULTS: For discrimination of non-STEMI (n = 165) in the entire study population (n = 784), the absolute δ change with the ROC-optimized value of 9.2 ng/L yielded an area under the curve of 0.898 and was superior to all relative δ changes (P < 0.0001). The positive predictive value for the absolute δ change was 48.7%, whereas the negative predictive value was 96.5%. In a specific ACS population with exclusion of STEMI (n = 342), the absolute δ change with the ROC-optimized value of 6.9 ng/L yielded a positive predictive value of 82.8% and a negative predictive value of 93.0%. In comparison to the ≥20% relative δ change, the ROC-optimized absolute δ change demonstrated a significantly added value for the entire study population and for the ACS cohort (net reclassification index 0.331 and 0.499, P < 0.0001). CONCLUSIONS: Absolute δ changes appear superior to relative δ changes in discriminating non-STEMI. A rise or fall of at least 9.2 ng/L in the entire study population and 6.9 ng/L in selected ACS patients seems adequate to rule-out non-STEMI. However, δ-values are useful to rule-in non-STEMI only in a specific ACS population.Keywords
Funding Information
- Roche Diagnostics Ltd
- Mitsubishi Chemicals
- Siemens Healthcare
- BRAHMS Biomarkers
- Clinical Diagnostics Division
- Thermo Fisher Scientific
This publication has 16 references indexed in Scilit:
- Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain — An evaluation with respect to the Universal Definition of Myocardial InfarctionClinica Chimica Acta; International Journal of Clinical Chemistry, 2011
- Troponin elevation in coronary vs. non-coronary diseaseEuropean Heart Journal, 2010
- Biological and Analytical Variability of a Novel High-Sensitivity Cardiac Troponin T AssayClinical Chemistry, 2010
- High-Sensitivity Cardiac Troponin T for Early Prediction of Evolving Non–ST-Segment Elevation Myocardial Infarction in Patients with Suspected Acute Coronary Syndrome and Negative Troponin Results on AdmissionClinical Chemistry, 2010
- 2007 Universal Myocardial Infarction Definition Change Criteria for Risk Stratification by Use of a High-Sensitivity Cardiac Troponin I AssayClinical Chemistry, 2010
- Frequency of Elevated Troponin I and Diagnosis of Acute Myocardial InfarctionThe American Journal of Cardiology, 2009
- Role of Monitoring Changes in Sensitive Cardiac Troponin I Assay Results for Early Diagnosis of Myocardial Infarction and Prediction of Risk of Adverse EventsClinical Chemistry, 2009
- Short- and Long-Term Biological Variation in Cardiac Troponin I Measured with a High-Sensitivity Assay: Implications for Clinical PracticeClinical Chemistry, 2009
- Universal Definition of Myocardial InfarctionCirculation, 2007
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart FailureClinical Chemistry, 2007